Molecular Diagnosis & Therapy

Papers
(The H4-Index of Molecular Diagnosis & Therapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
ADORA3: A Key Player in the Pathogenesis of Intracranial Aneurysms and a Potential Diagnostic Biomarker127
Predictive Ability of Serum Amino Acid Levels to Differentiate Fibromyalgia Patients from Healthy Subjects85
Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors71
Clinical Exome Reanalysis: Current Practice and Beyond56
Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date55
A Window of Opportunity for Newborn Screening46
Comment on “Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta‑Analysis”46
Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer43
Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate41
Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target38
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors38
Expression Signature of Immune-Related MicroRNAs in Autoimmune Skin Disease: Psoriasis and Vitiligo Insights33
Piflufolastat F 18: Diagnostic First Approval31
FAPI-Targeted Molecular Imaging: Transforming Insights into Post-Ischemic Myocardial Remodeling?31
Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecular Imaging Approach30
Evaluation of Minimal Residual Disease in Patients with Neuroblastoma30
Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk26
Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics24
Personalizing Oncolytic Immunovirotherapy Approaches24
Advances and Challenges in the Diagnosis of Leishmaniasis24
Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Central Nervous System Infections: Advances and Challenges23
Inflammatory Gene Panel Guiding the Study of Genetics in Inflammatory Bowel Disease23
Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders22
0.20740389823914